Research Article
Mass Spectrometry Amyloid Typing Is Reproducible across Multiple Organ Sites
Table 1
Clinical and laboratory characteristics of patients.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FLC, free light chains; MGUS, monoclonal gammopathy of undetermined significance; MM, multiple myeloma; ND, not determined; NS, nephrotic syndrome; RI, renal insufficiency (creatinine level ≥130 μmol/L); Mayo, Mayo Clinic staging system (1–3) based on troponin T and NT-proBNP levels. Reference range: FLC κ: 3.3–19.4 mg/L; FLC λ: 5.7–26.3 mg/L; FLC κ/λ ratio 0.26–1.65. |